SAN JOSE, Calif. – VitalConnect has received clearance from the U.S. Food and Drug Administration that extends the wear duration for the company’s existing Class 2 wearable biosensor, the VitalPatch, from four to five days. The VitalPatch biosensor is a single patient use and fully disposable device, and is suitable anywhere continuous monitoring is needed, including for post-discharge monitoring, remote patient monitoring and clinical trials. “The extended wear duration for our fully disposable VitalPatch biosensor supports our commitment toward improving patient care and enabling nurses and physicians to have real-time insight into their patients’ vitals and well-being,” said Dr. Nersi Nazari, CEO and founder of VitalConnect, in a statement. The clinical-grade VitalPatch tracks eight different biometric measurements continuously and in real-time: single-lead ECG (electrocardiography), heart rate, heart rate variability, respiratory rate, skin temperature, body posture, fall detection and activity.
You are here: / / FDA clears VitalPatch for extended use